psilocybin Archives - Page 2 of 2 - Green Market Report

Debra BorchardtDebra BorchardtMarch 30, 2020
mushroom.jpg?fit=960%2C640&ssl=1

4min27710

Medicinal mushroom company Champignon Brands Inc. (CSE: SHRM) has entered into a definitive agreement to acquire Tassili Life Sciences Corp. in an all-stock deal. Tassili will receive 16 million shares, which is roughly C$7.3 million.

The acquisition will expand Champignon’s preclinical trial pipeline, as well as its aggregation of broad intellectual property related to the development of novel psychedelics therapeutics and their delivery systems, targeting multiple pathological psychological diseases.

Tassili working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries (mTBI) and/or post-traumatic stress disorder (PTSD). The company is doing this in partnership with a multidisciplinary team of scientists and physicians at the University of Miami.

TRIALS UNDERWAY

Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, Tassili will conduct preclinical studies and eventually human clinical trials with the objective of demonstrating the safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or standalone PTSD.  The final results are expected in 2021.

Under the terms of the agreement with U of M, Tassili will retain all exclusive rights to inventions, data and IP discovery resulting from the studies which are being led by Dr. Michael Hoffer, professor of otolaryngology and neurological surgery at University of Miami’s Miller School of Medicine.

“Mild traumatic brain injury, especially concussion, is a significant cause of morbidity worldwide,” said Dr. Hoffer. “What many do not realize is that TBI often occurs alongside PTSD. Up to 40% of people impacted by mTBI, a head injury causing a temporary change in mental status or consciousness, or TBI in general, also suffer from PTSD. This combination of mTBI and PTSD is even more common in U.S military members and presents a vast patient population to service and potentially heal with our novel therapeutics under development.”

PSILOCYBIN PATENT PORTFOLIO

George Scorsis, Chairman of Tassili, said in a statement, “Our development program is championed by the University of Miami, a major U.S. research institution with a worldwide reputation in TBI research and treatment. Working with the University of Miami we aim to shift the mainstream perceptions about psychedelics by establishing the scientific underpinnings of the two compounds’ medical benefits and then developing a prescription-based therapeutic medicine for this combined disorder and a number of other disorders on the horizon, such as obsessive-compulsive disorder (OCD).”

In addition to the medical trials, Tassili has filed four provisional patents, one of which relates to its ongoing study with the University of Miami. In collaboration with university research institutes, Tassili said it intends to demonstrate that the clinical and physiological effects in PTSD and obsessive-compulsive disorder (OCD) is enhanced by timely measured dosages of psilocybin and cannabidiol, with superior clinical results as measured by objective outcomes.

The company said its vision is to administer a proven and proprietary combination of psilocybin and CBD in certified drug as well as psychotherapeutic clinics once human clinical trials are completed and the combination is approved by applicable regulatory agencies.

Management also believes that increased specificity to ensure approved, appropriate, standardized and dignified methods of treatment will result from novel delivery systems suiting recovery solutions to specific indications.  Three of the company’s provisional patents relate to this important part of the drug to patient relationship.

 


StaffStaffJanuary 21, 2020
shutterstock_1526869721-scaled.jpg?fit=720%2C960&ssl=1

3min27080

Just as the psilocybin mushroom market begins to heat up, one enterprising entrepreneur has quickly snapped up the trademark for the word “Psilocybin.” Marijuana Moment picked up on the founder’s notice on LinkedIn that the word had been trademarked. That post has since disappeared and while there is no mention of the trademark happening on the company’s website, the tiny TM does appear after each mention of the word Psilocybin on the company’s website.

The company sells chocolate bars, that don’t seem to contain any mushroom ingredients. In fact, there is little in the way of a description as to how the chocolate is made or sourced. It says the bars “have been created as a gateway to educate you on what is next for medicinal mushroom health and healing.” It does say that all the products are sold out.

Scarlet Ravin describes her company Psilocybin™️ as “a community-based support system holding a sacred knowing for others to come back to their knowing of their God-self.” She describes herself as being “known for her visionary Branding and Marketing which has led her companies to the front of the market allowing multiple press mentions and forward-thinking concepts that grab the attention of the mass market.”

Ravin told Marijuana Moment that she “plans to contribute 10 percent of profits to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is involved in researching the therapeutic benefits of psychedelic substances.”

Marijuana Trademarks Not Allowed

Psilocybin mushrooms are also a schedule 1 substance under the Controlled Substance Act like marijuana. The U.S. Patent Trade Office stated that marijuana is still prohibited from U.S. trademark registration. “The CSA prohibits, among other things, manufacturing, distributing, dispensing, or possessing certain controlled substances, including marijuana. 21 U.S.C. §§812, 841(a)(1), 844(a). Therefore, the USPTO refuses registration when an application identifies goods encompassing CBD or other extracts of marijuana because such goods are unlawful under federal law and do not support valid use of the applied-for mark in commerce.”

Marijuana Moment noted that this trademark is “Specifically for educational materials and it’s listed on the supplemental register, rather than the principal register, which means it would be incumbent upon the brand to prove that it has earned distinctiveness of the mark if the issue went to court.”

 

 

 



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 1 day

RT : The State of Cannabis SPACs was recorded on April 13, 2021. If you want to learn everything about SPACs in the cannabis i…

@GreenMarketRpt – 1 day

Not sure if you missed some news this week? Here’s a quick recap in #Psychedellux…

Back to Top

You have Successfully Subscribed!